Biologic Agents for Treatment of Rheumatoid Arthritis

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)


Volume 15, 3 Issues, 2016


Download PDF Flyer




Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Claudiu T. Supuran
Neurofarba Department
University of Florence
Florence
Italy


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Biologic Agents for Treatment of Rheumatoid Arthritis



Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 9(1): 8-23.

Author(s): Bulent Butun.

Affiliation: Chief of Physical Medicine and Rehabilitation Departmant, Chief of Rheumatology Unit, Akdeniz University Medical School Hospital, Antalya, Turkey.

Abstract

Rheumatoid arthritis (RA) is a chronic disease characterized by an immune mediated inflammatory synovitis that leads to joint destruction, functional impairment, and reduced quality of life. Thus, treatment goals should be longterm substantial relief of pain, arrested joint inflammation and damage, and improved function. Conventional (nonbiologic) DMARDs use is the first step of this debilitating disease treatment but in many patients, this is inadequate and other forms of therapy are required. Advances in the current knowledge of pathogenetic mechanisms of rheumatoid arthritis have contributed to the development of biological therapy, and translated research findings into clinical practice. TNF-alpha (infliximab, etanercept, adalimumab), IL-1 (anakinra) and IL-6 (tocilizumab) inhibitors, a B-cell depleting agent (rituximab) and a drug blocking T-cell costimulation (abatacept) have been approved for rheumatoid arthritis. In this text, the biologic therapies which are currently used in the patients with RA will be reviewed in the company of latest evidences.

Keywords:

Rheumatoid arthritis, biologic therapy, anti-TNF therapy, golimumab, certolizumab, abatacept, rituximab, tocilizumab.



Download Free Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 9
Issue Number: 1
First Page: 8
Last Page: 23
Page Count: 16
DOI: 10.2174/187152310790711692
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science